Home Compare DIM.PA vs SRT3.DE
Stock Comparison · Industry comparison · Medical Instruments & Supplies

Sartorius Stedim Biotech vs Sartorius Aktiengesellschaft: Which Stock Looks Stronger in 2026?

The structural profiles are close, with Sartorius Aktiengesellschaft carrying a narrow edge on growth. The remaining gap is narrow enough that the comparison remains open to different readings. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The comparison is mainly decided in growth, with the rest of the profile carrying less weight.

INDUSTRY COMPARISON

Both operate in: Medical Instruments & Supplies

This comparison is based on industry proximity, not on functional trajectory similarity. DIM.PA and SRT3.DE share the same industry classification.

For a similarity-based comparison, see how Sartorius Stedim Biotech and SRT3.DE each position within their functional peer groups in AssetNext.

Peer-Relative Score
DIM.PA
Sartorius Stedim Biotech S.A.
23
Peer-Score
Signal qualityHigh
vs
SRT3.DE
Sartorius Aktiengesellschaft
28
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The clearest separation appears in growth.

Dimension spread: DIM.PA vs SRT3.DE Profitability 25 25 Stability 18 21 Valuation 20 12 Growth 31 62 DIM.PA SRT3.DE
Gap Ranking
#1 Growth +31
#2 Valuation +8
#3 Stability +3
#4 Profitability
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for DIM.PA and SRT3.DE Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer DIM.PASRT3.DE Relative valuation Structural strength

The setup is mixed: neither company clearly combines the stronger profile with the more supportive price setup.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
On growth, Sartorius Aktiengesellschaft is positioned higher in the group, while Sartorius Stedim Biotech S.A. is closer to the middle.
Valuation
Both sit in the weaker half on valuation, with Sartorius Stedim Biotech S.A. still coming out ahead.
Growth — Dominant Gap
DIM.PA
31
SRT3.DE
62
Gap+31in favour of SRT3.DE

Earnings growth is one contributing factor within the growth lead.

What keeps the gap from being one-sided

Absolute pricing still looks more supportive for Sartorius Stedim Biotech, with a forward P/E that is 4.8 turns lower there.

What this means for the comparison

The main read on growth is clearer than the broader score gap.

Explore full peer positioning in AssetNext

Break down the DIM.PA vs SRT3.DE comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar growth-driven comparisons

Explore how DIM.PA and SRT3.DE each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.